 SAN DIEGO and TORONTO, Dec. 06, 2020 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Aptose NASDAQ: APTO, TSX: APS today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology ASH Annual Meeting. The Aptose management team reviewed the current clinical status of CG-806, Aptoses oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 ab trials, one trial in patients with relapsed or refractory acute myeloid leukemia AML, and the other trial in patients with relapsed or refractory B cell malignancies; and the team also reviewed the clinical status of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome MDS. 